CAJ | 학술논문

目的：分析缬沙坦对慢性心力衰竭患者治疗的量效关系。方法选取慢性充血性心力衰竭患者90例，随机分为3组，A组给予贝那普利10 mg/d治疗，B组给予缬沙坦80 mg/d治疗，C组给予缬沙坦320 mg/d治疗。观察3组患者治疗前及治疗6个月后血管紧张素Ⅱ( AngⅡ)、脑钠肽( BNP )及左室功能改善情况。结果治疗6个月3组患者未出现低血压、肾功能及血钾异常情况，心功能改善无显著差异（ P>0.05），C组短轴缩短率（FS）、心搏出量（SV）、左室射血分数（LVEF）水平高于A组及B组，左室收缩末内径（LVESD）及心脏左室舒张末内径（LVEDD）低于A组及B组，AngⅡ及BNP均低于A组和B组（ P<0.05）。结论大剂量缬沙坦能够明显改善左室功能重构，有效提高心功能，对血管紧张素及脑钠肽水平的控制优于小剂量缬沙坦及贝那普利，安全性良好，值得临床推广。
목적：분석힐사탄대만성심력쇠갈환자치료적량효관계。방법선취만성충혈성심력쇠갈환자90례，수궤분위3조，A조급여패나보리10 mg/d치료，B조급여힐사탄80 mg/d치료，C조급여힐사탄320 mg/d치료。관찰3조환자치료전급치료6개월후혈관긴장소Ⅱ( AngⅡ)、뇌납태( BNP )급좌실공능개선정황。결과치료6개월3조환자미출현저혈압、신공능급혈갑이상정황，심공능개선무현저차이（ P>0.05），C조단축축단솔（FS）、심박출량（SV）、좌실사혈분수（LVEF）수평고우A조급B조，좌실수축말내경（LVESD）급심장좌실서장말내경（LVEDD）저우A조급B조，AngⅡ급BNP균저우A조화B조（ P<0.05）。결론대제량힐사탄능구명현개선좌실공능중구，유효제고심공능，대혈관긴장소급뇌납태수평적공제우우소제량힐사탄급패나보리，안전성량호，치득림상추엄。
Objective To observe and analyze the dose effect relationship of valsartan in the treatment of patients with chronic heart failure. Methods 90 cases of chronic congestive heart failure were selected as the research subjects and randomly divided into three groups. The group A was given benazepril 10 mg/d, the group B was given valsartan 80 mg/d and the group C was given valsartan 320 mg/d. The angiotensin II, BNP levels and left ventricular function improvement before treatment and after 6-month treatment were observed and analyzed in the three groups. Results No hypotension and the abnormalities of renal function and serum potassium after 6-month treatment appeared in the three groups, and the improvement of heart function had no significant difference ( P > 0. 05 ) , FS, SV and LVEF levels after 6-month treatment in the group C were higher than those in the group A and B, whereas LVESD and LVEDD were lower than those in the group A and B, the angiotensin II and brain natriuretic peptide levels were lower than those in the group A and B, differences were statistically significant ( P < 0. 05 ) . Conclusion Large dose of valsartan can significantly improve the left ventricular function remodeling, effectively improve the heart function, is superior to small doses of valsartan and benazepril in controlling angiotensin and brain natriuretic peptide levels, has good security and is worthy of clinical promotion and application .